| Beri O Songna, MD | |
|
38 Tyler St, Nashua, NH 03060-2912 | |
| (603) 577-5377 | |
| (603) 577-5395 |
| Full Name | Beri O Songna |
|---|---|
| Gender | Female |
| Speciality | Nephrology |
| Experience | 13 Years |
| Location | 38 Tyler St, Nashua, New Hampshire |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134412182 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | LT4184 (New Hampshire) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Nashua Dialysis | Nashua, NH | Dialysis facility |
| Steam Dialysis (derry) | Londonderry, NH | Dialysis facility |
| Southern Nh Medical Center | Nashua, NH | Hospital |
| St Joseph Hospital | Nashua, NH | Hospital |
| Mary Hitchcock Memorial Hospital | Lebanon, NH | Hospital |
| Elliot Hospital | Manchester, NH | Hospital |
| Catholic Medical Center | Manchester, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Foundation Medical Partners Inc | 9436140456 | 280 |
News Archive
Postmenopausal women who have experienced loss of all teeth are at higher risk of developing high blood pressure, according to a recent University at Buffalo study published in the American Journal of Hypertension. Multiple studies have suggested an association between periodontal disease and tooth loss with hypertension, but the relationship with time remains unclear with these associations.
Penn Medicine will establish the Philadelphia region's first dedicated center for the treatment and research of blood diseases by combining the expertise of physicians who specialize in the care of blood disorder patients of all ages along with basic science and clinical researchers who are working to advance treatments for these illnesses.
The study brings together the results of more than ten years of monitoring 116 patients affected by varicose ulcers being treated in Granada, Pamplona and Madrid. On comparing these with data from other novel therapies
Ocular Therapeutix, Inc. announces the start of its Phase 3 clinical program to evaluate the safety and efficacy of their sustained release dexamethasone, an ophthalmic corticosteroid for the treatment of post-operative inflammation and pain following cataract surgery. Ocular Therapeutix's dexamethasone is administered as a one-time, bioabsorbable intracanalicular plug for release of the steroid to the ocular surface for up 30 days.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that the United States Patent and Trademark Office (USPTO) has extended by five years the U.S. Patent No. 6,028,071, which covers FOLOTYN (pralatrexate injection).
› Verified 6 days ago
| Entity Name | Foundation Medical Partners Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033162037 PECOS PAC ID: 9436140456 Enrollment ID: O20040519001048 |
News Archive
Postmenopausal women who have experienced loss of all teeth are at higher risk of developing high blood pressure, according to a recent University at Buffalo study published in the American Journal of Hypertension. Multiple studies have suggested an association between periodontal disease and tooth loss with hypertension, but the relationship with time remains unclear with these associations.
Penn Medicine will establish the Philadelphia region's first dedicated center for the treatment and research of blood diseases by combining the expertise of physicians who specialize in the care of blood disorder patients of all ages along with basic science and clinical researchers who are working to advance treatments for these illnesses.
The study brings together the results of more than ten years of monitoring 116 patients affected by varicose ulcers being treated in Granada, Pamplona and Madrid. On comparing these with data from other novel therapies
Ocular Therapeutix, Inc. announces the start of its Phase 3 clinical program to evaluate the safety and efficacy of their sustained release dexamethasone, an ophthalmic corticosteroid for the treatment of post-operative inflammation and pain following cataract surgery. Ocular Therapeutix's dexamethasone is administered as a one-time, bioabsorbable intracanalicular plug for release of the steroid to the ocular surface for up 30 days.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that the United States Patent and Trademark Office (USPTO) has extended by five years the U.S. Patent No. 6,028,071, which covers FOLOTYN (pralatrexate injection).
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Beri O Songna, MD Po Box 3677, Nashua, NH 03061-3677 Ph: (603) 577-7900 | Beri O Songna, MD 38 Tyler St, Nashua, NH 03060-2912 Ph: (603) 577-5377 |
News Archive
Postmenopausal women who have experienced loss of all teeth are at higher risk of developing high blood pressure, according to a recent University at Buffalo study published in the American Journal of Hypertension. Multiple studies have suggested an association between periodontal disease and tooth loss with hypertension, but the relationship with time remains unclear with these associations.
Penn Medicine will establish the Philadelphia region's first dedicated center for the treatment and research of blood diseases by combining the expertise of physicians who specialize in the care of blood disorder patients of all ages along with basic science and clinical researchers who are working to advance treatments for these illnesses.
The study brings together the results of more than ten years of monitoring 116 patients affected by varicose ulcers being treated in Granada, Pamplona and Madrid. On comparing these with data from other novel therapies
Ocular Therapeutix, Inc. announces the start of its Phase 3 clinical program to evaluate the safety and efficacy of their sustained release dexamethasone, an ophthalmic corticosteroid for the treatment of post-operative inflammation and pain following cataract surgery. Ocular Therapeutix's dexamethasone is administered as a one-time, bioabsorbable intracanalicular plug for release of the steroid to the ocular surface for up 30 days.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that the United States Patent and Trademark Office (USPTO) has extended by five years the U.S. Patent No. 6,028,071, which covers FOLOTYN (pralatrexate injection).
› Verified 6 days ago
Christopher Michael Riccio, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 17 Prospect St, Nashua, NH 03060 Phone: 603-594-6337 Fax: 603-594-6330 | |
Dr. Mark Liebling, Nephrology Medicare: Medicare Enrolled Practice Location: 166 Kinsley St Ste 301, Nashua, NH 03060 Phone: 603-883-5673 Fax: 603-689-1343 | |
Dr. Chengta Richard Dai, MD Nephrology Medicare: Medicare Enrolled Practice Location: 168 Kinsley Street, Suite 20, Nashua, NH 03060 Phone: 603-578-9363 Fax: 603-578-9539 | |
Dr. William Stephan, M.D. Nephrology Medicare: Not Enrolled in Medicare Practice Location: 168 Kinsley St, Nashua, NH 03060 Phone: 603-889-4131 | |
Ihab M Ziada, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 173 Daniel Webster Hwy, Nashua, NH 03060 Phone: 603-891-4500 | |
Ajay K Sharma, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 8 Prospect St, Nashua, NH 03060 Phone: 603-577-2039 Fax: 603-882-5656 | |
Dr. Gianfranco Tulliano, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 8 Prospect St, Nashua, NH 03060 Phone: 603-577-2045 Fax: 603-577-5644 |